Kargl J, Andersen L, Hasenöhrl C, Feuersinger D, Stančić A, Fauland A, Magnes C, El-Heliebi A, Lax S, Uranitsch S, Haybaeck J, Heinemann A, Schicho R
Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
HEALTH - Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft m.b.H., Graz, Austria.
Br J Pharmacol. 2016 Jan;173(1):142-54. doi: 10.1111/bph.13345. Epub 2015 Nov 25.
Tumour cell migration and adhesion constitute essential features of metastasis. G-protein coupled receptor 55 (GPR55), a lysophospholipid receptor, has been shown to play an important role in carcinogenesis. Here, we investigated the involvement of GPR55 in migration and metastasis of colon cancer cells.
Adhesion and migration assays using the highly metastatic colon cancer cell line HCT116 and an in vivo assay of liver metastasis were performed. The GPR55 antagonist CID16020046, cannabidiol, a putative GPR55 antagonist and GPR55 siRNA were used to block GPR55 activity in HCT116 colon cancer cells.
HCT116 cells showed a significant decrease in adhesion to endothelial cells and in migration after blockade with CID16020046 or cannabidiol. The inhibitory effects of CID16020046 or cannabidiol were averted by GPR55 siRNA knock down in cancer cells. The integrity of endothelial cell monolayers was increased after pretreatment of HCT116 cells with the antagonists or after GPR55 siRNA knockdown while pretreatment with lysophosphatidylinositol (LPI), the endogenous ligand of GPR55, decreased integrity of the monolayers. LPI also induced migration in GPR55 overexpressing HCT116 cells that was blocked by GPR55 antagonists. In a mouse model of metastasis, the arrest of HCT116 cancer cells in the liver was reduced after treatment with CID16020046 or cannabidiol. Increased levels of LPI (18:0) were found in colon cancer patients when compared with healthy individuals.
GPR55 is involved in the migratory behaviour of colon carcinoma cells and may serve as a pharmacological target for the prevention of metastasis. © 2015 The British Pharmacological Society.
肿瘤细胞迁移和黏附是转移的基本特征。G蛋白偶联受体55(GPR55)作为一种溶血磷脂受体,已被证明在肿瘤发生中起重要作用。在此,我们研究了GPR55在结肠癌细胞迁移和转移中的作用。
使用高转移性结肠癌细胞系HCT116进行黏附与迁移实验,并进行肝转移的体内实验。使用GPR55拮抗剂CID16020046、大麻二酚(一种假定的GPR55拮抗剂)和GPR55小干扰RNA来阻断HCT116结肠癌细胞中的GPR55活性。
用CID16020046或大麻二酚阻断后,HCT116细胞对内皮细胞的黏附及迁移能力显著降低。癌细胞中GPR55小干扰RNA敲低可消除CID16020046或大麻二酚的抑制作用。用拮抗剂预处理HCT116细胞或进行GPR55小干扰RNA敲低后,内皮细胞单层的完整性增加,而用GPR55的内源性配体溶血磷脂酰肌醇(LPI)预处理则降低了单层的完整性。LPI还可诱导过表达GPR55的HCT116细胞迁移,该迁移被GPR55拮抗剂阻断。在转移小鼠模型中,用CID16020046或大麻二酚治疗后,HCT116癌细胞在肝脏中的滞留减少。与健康个体相比,结肠癌患者体内LPI(18:0)水平升高。
GPR55参与结肠癌细胞的迁移行为,可能作为预防转移的药理学靶点。©2015英国药理学会。